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of thrombosis and whether DAPT should be individualized according to stent type or
lesion or patient subsets is unknown. The Patient Related Outcomes with Endeavor versus
Cypher Stenting Trial (PROTECT) was designed and powered to compare long-term
outcomes of safety endpoints such as ST between the Endeavor zotarolimus-eluting stent
(E-ZES) and the Cypher sirolimus-eluting stent (C-SES).
Methods: PROTECT is a prospective, multicenter, randomized trial conducted at 196
sites in 36 countries worldwide in all continents. Patients with up to 4 coronary lesions
amenable for stenting were randomized to receive E-ZES or C-SES. The primary
endpoint is the 3 year rate of ARC-defined definite and probable ST. DAPT with
clopidogrel and aspirin were prescribed at least for 3 months and at physician discretion
for 12 months or longer. Planned and actual duration of DAPT, utilization of aspirin
(ASA) and clopidogrel by region, and aspirin dose (100mg, 100-300 mg, 300mg)
were collected. Multivariate regression analysis will be used to identify predictors for
DAPT duration of 12 months, DAPT compliance, and the relationship of these factors
with the outcomes of ST, myocardial infarction and cardiac death.
Results: PROTECT enrolled 8,800 patients; mean age 62.210.6 years and 76.3% were
male. Overall, 44.7% of patients presented with acute coronary syndromes, 27.2% had
diabetes mellitus, 20.5% prior MI, and 12.5% prior PCI. Almost all were de novo lesions
(98.2%), 46.6% in the left anterior descending artery and 54.8% were B2/C lesions.
Details of DAPT usage (planned and actual duration, ASA dosage) by region, and
according to patient characteristics will be available for presentation.
Conclusions: Analysis of the variation in duration of DAPT across regions and according
to patient characteristics in a real world setting will further our understanding of the
impact of DAPT on stent specific and global cardiovascular outcomes.
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Background: Platelet activation plays a critical role in the pathogenesis of acute
myocardial infarction (AMI). This study aimed to determine whether the results of platelet
function assays used to measure response to clopidogrel therapy are similar among
patients with stable CAD and those with AMI undergoing percutaneous coronary
intervention (PCI) both at the index admission and at 30 days’ post admission.
Methods: Sixty patients were prospectively enrolled into either an elective PCI cohort or
an AMI cohort. Patients presenting with an AMI were approached within 24 hours of
presentation and following PCI for participation. Patients underwent platelet function
testing post-PCI and again at 30 days ( 2 weeks) follow up. Tests included vasodilator
stimulated phosphoprotein phosphorylation (VASP) and VerifyNow P2Y12.
Results: The average age of the population was 64.5  11.2 years with no difference
between the elective and AMI groups. Baseline characteristics were similar, with an
overall rate of diabetes of 26.7%, hypertension 78.3%, current smokers 15.0%, prior CAD
35.0%, renal insufficiency 6.7% and the average BMI was 31  7. The AMI group had
higher PRU, percent inhibition, and PRI at the time of PCI as compared to the elective PCI
group. This difference was not sustained at 30 days. The PRU significantly decreased at
30 days compared to the PCI procedure for the AMI group. Similarly, the percent
inhibition and PRI decreased, but did not achieve statistical significance. (Table).
Conclusions: Platelet reactivity is higher at the time of primary PCI (vs. elective PCI)
with AMI presentation. These data support the notion that the platelets become
hypersensitive at the time of AMI and are passivated over time given antiplatelet therapy.
The on-treatment platelet reactivity should be assessed for patients presenting with AMI
to appropriately tailor the antiplatelet regime.
Elective AMI P Value
Index Procedure
PRU 159.13	/ 93.01 202.97	/ 99.85 0.095
Percent Inhibition 45.57	/ 30.03 23.73	/ 29.86 0.008
VASP-PRI 30.40	/ 24.03 52.63	/ 20.02 0.001
Platelet count 196.19	/ 66.86 218.46	/ 63.70 0.201
AST 27.55	/ 24.88 90.92	/ 88.36 0.002
30 Days Follow
Up
PRU 180.00	/ 93.64 189.52	/ 86.86 0.738
Percent Inhibition 38.28	/ 30.00 31.61	/ 26.94 0.459
VASP-PRI 41.79	/ 22.60 47.92	/ 23.76 0.407
Platelet count 235.35	/ 72.56 243.61	/ 50.50 0.673
Index Procedure 30 Days Follow Up P Value (paired)
Elective
PRU 159.13	/ 93.01 180.00	/ 93.64 0.125
Percent Inhibition 45.57	/ 30.03 38.28	/ 30.00 0.445
VASP-PRI 30.40	/ 24.03 41.79	/ 22.60 0.032
Platelet count 196.19	/ 66.86 235.35	/ 72.56 0.009
AMI
PRU 202.97	/ 99.85 189.52	/ 86.86 0.003
Percent Inhibition 23.73	/ 29.86 31.61	/ 26.94 0.195
VASP-PRI 52.63	/ 20.02 47.92	/ 23.76 0.349
Platelet Count 218.46	/ 63.70 243.61	/ 50.50 0.001
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Background: In patients with ST elevation myocardial infarction (STEMI) undergoing
primary percutaneous coronary intervention (pPCI) ticagrelor 180mg loading dose (LD)
exhibits a delayed onset of action – from what would be predicted based on assessments
in stable patients. Since Cmax for ticagrelor and its main metabolite increases approxi-
mately dose-proportionately, we hypothesized that doubling the ticagrelor LD in patients
with STEMI undergoing pPCI may lead to faster early platelet inhibition.
Methods: This is a prospective, pharmacodynamic study in P2Y12 inhibitor naïve
patients with STEMI (onset of pain12 hours) undergoing pPCI. Patients after informed
consent received 360mg LD of ticagrelor immediately before pPCI. Platelet reactivity
(PR) was assessed with VerifyNow assay in platelet reactivity units (PRU) immediately
before LD (Hour 0) and at 0.5, 1, 2 and Hour 4 after LD.
Results: Data of 24 patients are presented (79.2%men, mean age 54.79.5 years). At
hour 0 mean PR was 226.866.8 PRU. At hour 0.5, 1, 2 and 4 PR was 272.4 (252.0-292.7
95% CIs), 227.3 (190.2-264.4 95%CIs), 134.7 (85.0-184.3 95%CIs) and 56.8(24.1-89.4
95%CIs) respectively. A statistical significant reduction in PR was observed between
Hour 0 and Hour 2, with a mean difference of -89.9 PRU (-15.1 to -164.8 95%CIs,
p0.01). A statistical significant increase in PR was observed between Hour 0 and Hour
0.5, with a mean difference of 47.8 PRU (17.2 to 78.5 95% CIs, p0.001) PR mean
difference between Hour 1-Hour 2 and Hour 2-Hour 4 was also significant (-92.6 PRU,
-159.8 to -25.4 95%CIs, p0.003 and -77.9 PRU, -135.3 to -20.5, p0.004). No major
adverse cardiovascular events or bleeding events observed until discharge.
Conclusions: In P2Y12 inhibitors naïve STEMI patients undergoing pPCI, an initial
delay in the onset of ticagrelor’s antiplatelet action until Hour 1 is observed, despite the
doubling of the loading dose.
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Background: No data exit regarding the association between aspirin / clopidogrel
resistance and intra-stent thrombi on follow-up optical coherence tomography (OCT)
following drug-eluting stents (DES) implantation. So we measured the presence of
intra-stent thrombi in OCT and aspirin reaction unit (ARU), P2Y12 reaction unit (PRU),
inhibition ratio of PRU in patients with drug eluting stent (DES).
Methods: From our OCT registry, a total of 313 patients treated with DES underwent
follow-up OCT and performed the measurement of aspirin reaction unit (ARU), P2Y12
reaction unit (PRU), inhibition ratio of PRU using VerifyNow (VN) on the same day for
follow-up OCT. Aspirin and clopidogrel resistance were defined as ARU550 and PRU
250, respectively. For assessing whether aspirin / clopidogrel resistance could be related
to intra-stent thrombi on OCT, we divided the patients according to the presence of aspirin
or clopidogrel resistance, and then compared the occurrence of intra-stent thrombi on
OCT between the patients with or without resistance.
Results: Mean OCT follow-up duration of enrolled 313 patients was 195133 days.
According to the presence of aspirin / clopidogrel resistance, there was no significant
difference in the occurrence of intra-stent thrombi on OCT. On the assessment according
to the major risk factors of coronary artery disease, there was also no significant difference
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